This was the stock's third consecutive day of losses.

And Catalyst Pharmaceuticals stock is one of those that seems to be thriving. Catalyst is Thursday's selection for IBD 50 ...

Supernus Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 81. Please watch the ...

Renaissance Investment Management, an investment management company, released its Q4 2024 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The Russell 2000 ...

Catalyst Pharmaceuticals Stock Performance Catalyst Pharmaceuticals stock opened at $24.46 on Thursday. The firm has a market cap of $2.97 billion, a price-to-earnings ratio of 20.73, a price-to ...

Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven ...

Farther Finance Advisors LLC raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 125.1% during the fourth quarter, according to the company in its most recent 13F ...

Catalyst has been a top-rated stock at MAPsignals for a few years. That means the stock has unusual buy pressure and growing ...

A major breakthrough in liquid catalysis is transforming how essential products are made, making the chemical manufacturing ...

Shares of Catalyst Pharmaceuticals Inc. CPRX shed 1.43% to $24.11 Thursday, on what proved to be an all-around grim trading ...